Ausschreibung: Arzneimittel - NO-Vadsø Arzneimittel Dokument Nr...: 205573-2020 (ID: 2020050409171118760) Veröffentlicht: 04.05.2020 * NO-Vadsø: Arzneimittel 2020/S 86/2020 205573 Freiwillige Ex-ante-Transparenzbekanntmachung Lieferauftrag Rechtsgrundlage: Richtlinie 2014/24/EU Abschnitt I: Öffentlicher Auftraggeber/Auftraggeber I.1)Name und Adressen Offizielle Bezeichnung: Sykehusinnkjøp HF Nationale Identifikationsnummer: 916879067 Postanschrift: Postboks 40 Ort: Vadsø NUTS-Code: NO Postleitzahl: 9811 Land: Norwegen Kontaktstelle(n): Ninja Elise Seippel E-Mail: [6]ninja.elise.seippel@sykehusinnkjop.no Internet-Adresse(n): Hauptadresse: [7]https://permalink.mercell.com/128638226.aspx Adresse des Beschafferprofils: [8]http://www.sykehusinnkjop.no/ I.4)Art des öffentlichen Auftraggebers Einrichtung des öffentlichen Rechts I.5)Haupttätigkeit(en) Gesundheit Abschnitt II: Gegenstand II.1)Umfang der Beschaffung II.1.1)Bezeichnung des Auftrags: Additional Contract LIS 2001c Labetolol Referenznummer der Bekanntmachung: 2018/890 II.1.2)CPV-Code Hauptteil 33600000 II.1.3)Art des Auftrags Lieferauftrag II.1.4)Kurze Beschreibung: Sykehusinnkjøp HF, Divisjon legemidler (LIS) is collecting tenders for medicines that are used by the Health Trusts. LIS has previously announced and implemented an open tender competition for parenteral special pharmaceutical preparations (LIS 2001c). The competition includes active ingredients in accordance with the tender documentation, annex 3: the Active Ingredients List. A new need has arisen after the contracts were signed for contracts for the delivery of Labetolol for infusion (ATC code C07AG01) as the selected supplier has announced that the delivery of their product cannot be maintained. II.1.6)Angaben zu den Losen Aufteilung des Auftrags in Lose: nein II.1.7)Gesamtwert der Beschaffung (ohne MwSt.) Wert ohne MwSt.: 2 100 000.00 NOK II.2)Beschreibung II.2.1)Bezeichnung des Auftrags: II.2.2)Weitere(r) CPV-Code(s) II.2.3)Erfüllungsort NUTS-Code: NO01 II.2.4)Beschreibung der Beschaffung: Sykehusinnkjøp HF, Divisjon legemidler (LIS) is collecting tenders for medicines that are used by the Health Trusts. LIS has previously announced and implemented an open tender competition for parenteral special pharmaceutical preparations (LIS 2001c). The competition includes active ingredients in accordance with the tender documentation, annex 3: the Active Ingredients List. A new need has arisen after the contracts were signed for contracts for the delivery of Labetolol for infusion (ATC code C07AG01) as the selected supplier has announced that the delivery of their product cannot be maintained. Due to this, LIS intends to enter into contracts between the regional health trusts (the contracting authorities) and Macure Pharma ApS (the supplier) as an additional contract to LIS 2001c, i.e., the scope and length of the contract must follow the mentioned procurement. (Hereunder access to extension and cancellation), without the announcement of a new competition for this active ingredient. The health companies that are under the regional health trusts have an option to join the contracts. LIS has explored the market situation and is of the opinion that it is not possible to hold a new contest, or that a supplier other than Macure Pharma ApS can deliver the product in the contract period, and that the situation that has occurred is not the contracting authoritys fault, nor something that the contracting authority could predict. LIS therefore believes that there are grounds to make the procurement without a competition. Refer to the public procurement regulation § 21-5, cf. § 21-2, cf. § 13-4 letter b no. 3 and letter cf. also § 13-3 letter e. LIS requests that those who have objections to this submit feedback before the waiting period expires on 7 May 2020. If no objections are received, a contract will be signed after the waiting period has expired. II.2.5)Zuschlagskriterien Preis II.2.11)Angaben zu Optionen Optionen: nein II.2.13)Angaben zu Mitteln der Europäischen Union Der Auftrag steht in Verbindung mit einem Vorhaben und/oder Programm, das aus Mitteln der EU finanziert wird: nein II.2.14)Zusätzliche Angaben Abschnitt IV: Verfahren IV.1)Beschreibung IV.1.1)Verfahrensart Auftragsvergabe ohne vorherige Bekanntmachung eines Aufrufs zum Wettbewerb im Amtsblatt der Europäischen Union (für die unten aufgeführten Fälle) * Der Auftrag fällt nicht in den Anwendungsbereich der Richtlinie Erläuterung: Sykehusinnkjøp HF, Divisjon legemidler (LIS) is collecting tenders for medicines that are used by the Health Trusts. LIS has previously announced and implemented an open tender competition for parenteral special pharmaceutical preparations (LIS 2001c). The competition includes active ingredients in accordance with the tender documentation, annex 3: the Active Ingredients List. A new need has arisen after the contracts were signed for contracts for the delivery of Labetolol for infusion (ATC code C07AG01) as the selected supplier has announced that the delivery of their product cannot be maintained. Due to this, LIS intends to enter into contracts between the regional health trusts (the contracting authorities) and Macure Pharma ApS (the supplier) as an additional contract to LIS 2001c, i.e., the scope and length of the contract must follow the mentioned procurement. (Hereunder access to extension and cancellation), without the announcement of a new competition for this active ingredient. The health companies that are under the regional health trusts have an option to join the contracts. LIS has explored the market situation and is of the opinion that it is not possible to hold a new contest, or that a supplier other than Macure Pharma ApS can deliver the product in the contract period, and that the situation that has occurred is not the contracting authoritys fault, nor something that the contracting authority could predict. LIS therefore believes that there are grounds to make the procurement without a competition. Refer to the public procurement regulation § 21-5, cf. § 21-2, cf. § 13-4 letter b no. 3 and letter cf. also § 13-3 letter e. LIS requests that those who have objections to this submit feedback before the waiting period expires on 7 May 2020. If no objections are received, a contract will be signed after the waiting period has expired. IV.1.3)Angaben zur Rahmenvereinbarung IV.1.8)Angaben zum Beschaffungsübereinkommen (GPA) Der Auftrag fällt unter das Beschaffungsübereinkommen: ja IV.2)Verwaltungsangaben IV.2.1)Frühere Bekanntmachung zu diesem Verfahren Abschnitt V: Auftragsvergabe/Konzessionsvergabe Auftrags-Nr.: 1 V.2)Auftragsvergabe/Konzessionsvergabe V.2.1)Tag der Zuschlagsentscheidung: 27/04/2020 V.2.2)Angaben zu den Angeboten Der Auftrag wurde an einen Zusammenschluss aus Wirtschaftsteilnehmern vergeben: nein V.2.3)Name und Anschrift des Auftragnehmers/Konzessionärs Offizielle Bezeichnung: Macure Pharma ApS Nationale Identifikationsnummer: 35234748 Postanschrift: Hejrevej 39 Ort: København NUTS-Code: DK Postleitzahl: 2400 Land: Dänemark Der Auftragnehmer/Konzessionär wird ein KMU sein: nein V.2.4)Angaben zum Wert des Auftrags/Loses/der Konzession (ohne MwSt.) Ursprünglich veranschlagter Gesamtwert des Auftrags/Loses/der Konzession: 2 100 000.00 NOK Gesamtwert des Auftrags/des Loses/der Konzession: 2 100 000.00 NOK V.2.5)Angaben zur Vergabe von Unteraufträgen Abschnitt VI: Weitere Angaben VI.3)Zusätzliche Angaben: VI.4)Rechtsbehelfsverfahren/Nachprüfungsverfahren VI.4.1)Zuständige Stelle für Rechtsbehelfs-/Nachprüfungsverfahren Offizielle Bezeichnung: Øst-Finnmark tingrett Postanschrift: Postboks 54 Ort: Vadsø Postleitzahl: 9811 Land: Norwegen Internet-Adresse: [9]https://www.domstol.no/Enkelt-domstol/ost-finnmark-tingrett/ VI.4.2)Zuständige Stelle für Schlichtungsverfahren Offizielle Bezeichnung: Klagenemda for offentlige anskaffelser Postanschrift: Postboks 439 Sentrum Ort: Bergen Postleitzahl: 5805 Land: Norwegen E-Mail: [10]postmottak@kofa.no Telefon: +47 55597500 Internet-Adresse: [11]http://www.kofa.no VI.4.3)Einlegung von Rechtsbehelfen VI.4.4)Stelle, die Auskünfte über die Einlegung von Rechtsbehelfen erteilt VI.5)Tag der Absendung dieser Bekanntmachung: 29/04/2020 References 6. mailto:ninja.elise.seippel@sykehusinnkjop.no?subject=TED 7. https://permalink.mercell.com/128638226.aspx 8. http://www.sykehusinnkjop.no/ 9. https://www.domstol.no/Enkelt-domstol/ost-finnmark-tingrett/ 10. mailto:postmottak@kofa.no?subject=TED 11. http://www.kofa.no/ OT: 04/05/2020 S86 Supplies - Voluntary ex ante transparency notice - Contract award without prior publication Norway-Vadsø: Pharmaceutical products 2020/S 086-205573 Voluntary ex ante transparency notice Supplies Legal Basis: Directive 2014/24/EU Section I: Contracting authority/entity I.1)Name and addresses Official name: Sykehusinnkjøp HF National registration number: 916879067 Postal address: Postboks 40 Town: Vadsø NUTS code: NO Postal code: 9811 Country: Norway Contact person: Ninja Elise Seippel E-mail: [6]ninja.elise.seippel@sykehusinnkjop.no Internet address(es): Main address: [7]https://permalink.mercell.com/128638226.aspx Address of the buyer profile: [8]http://www.sykehusinnkjop.no/ I.4)Type of the contracting authority Body governed by public law I.5)Main activity Health Section II: Object II.1)Scope of the procurement II.1.1)Title: Additional Contract LIS 2001c Labetolol Reference number: 2018/890 II.1.2)Main CPV code 33600000 II.1.3)Type of contract Supplies II.1.4)Short description: Sykehusinnkjøp HF, Divisjon legemidler (LIS) is collecting tenders for medicines that are used by the Health Trusts. LIS has previously announced and implemented an open tender competition for parenteral special pharmaceutical preparations (LIS 2001c). The competition includes active ingredients in accordance with the tender documentation, annex 3: the Active Ingredients List. A new need has arisen after the contracts were signed for contracts for the delivery of Labetolol for infusion (ATC code C07AG01) as the selected supplier has announced that the delivery of their product cannot be maintained. II.1.6)Information about lots This contract is divided into lots: no II.1.7)Total value of the procurement (excluding VAT) Value excluding VAT: 2 100 000.00 NOK II.2)Description II.2.1)Title: II.2.2)Additional CPV code(s) II.2.3)Place of performance NUTS code: NO01 II.2.4)Description of the procurement: Sykehusinnkjøp HF, Divisjon legemidler (LIS) is collecting tenders for medicines that are used by the Health Trusts. LIS has previously announced and implemented an open tender competition for parenteral special pharmaceutical preparations (LIS 2001c). The competition includes active ingredients in accordance with the tender documentation, annex 3: the Active Ingredients List. A new need has arisen after the contracts were signed for contracts for the delivery of Labetolol for infusion (ATC code C07AG01) as the selected supplier has announced that the delivery of their product cannot be maintained. Due to this, LIS intends to enter into contracts between the regional health trusts (the contracting authorities) and Macure Pharma ApS (the supplier) as an additional contract to LIS 2001c, i.e., the scope and length of the contract must follow the mentioned procurement. (Hereunder access to extension and cancellation), without the announcement of a new competition for this active ingredient. The health companies that are under the regional health trusts have an option to join the contracts. LIS has explored the market situation and is of the opinion that it is not possible to hold a new contest, or that a supplier other than Macure Pharma ApS can deliver the product in the contract period, and that the situation that has occurred is not the contracting authoritys fault, nor something that the contracting authority could predict. LIS therefore believes that there are grounds to make the procurement without a competition. Refer to the public procurement regulation § 21-5, cf. § 21-2, cf. § 13-4 letter b no. 3 and letter cf. also § 13-3 letter e. LIS requests that those who have objections to this submit feedback before the waiting period expires on 7 May 2020. If no objections are received, a contract will be signed after the waiting period has expired. II.2.5)Award criteria Price II.2.11)Information about options Options: no II.2.13)Information about European Union funds The procurement is related to a project and/or programme financed by European Union funds: no II.2.14)Additional information Section IV: Procedure IV.1)Description IV.1.1)Type of procedure Award of a contract without prior publication of a call for competition in the Official Journal of the European Union in the cases listed below * The procurement falls outside the scope of application of the directive Explanation: Sykehusinnkjøp HF, Divisjon legemidler (LIS) is collecting tenders for medicines that are used by the Health Trusts. LIS has previously announced and implemented an open tender competition for parenteral special pharmaceutical preparations (LIS 2001c). The competition includes active ingredients in accordance with the tender documentation, annex 3: the Active Ingredients List. A new need has arisen after the contracts were signed for contracts for the delivery of Labetolol for infusion (ATC code C07AG01) as the selected supplier has announced that the delivery of their product cannot be maintained. Due to this, LIS intends to enter into contracts between the regional health trusts (the contracting authorities) and Macure Pharma ApS (the supplier) as an additional contract to LIS 2001c, i.e., the scope and length of the contract must follow the mentioned procurement. (Hereunder access to extension and cancellation), without the announcement of a new competition for this active ingredient. The health companies that are under the regional health trusts have an option to join the contracts. LIS has explored the market situation and is of the opinion that it is not possible to hold a new contest, or that a supplier other than Macure Pharma ApS can deliver the product in the contract period, and that the situation that has occurred is not the contracting authoritys fault, nor something that the contracting authority could predict. LIS therefore believes that there are grounds to make the procurement without a competition. Refer to the public procurement regulation § 21-5, cf. § 21-2, cf. § 13-4 letter b no. 3 and letter cf. also § 13-3 letter e. LIS requests that those who have objections to this submit feedback before the waiting period expires on 7 May 2020. If no objections are received, a contract will be signed after the waiting period has expired. IV.1.3)Information about framework agreement IV.1.8)Information about the Government Procurement Agreement (GPA) The procurement is covered by the Government Procurement Agreement: yes IV.2)Administrative information IV.2.1)Previous publication concerning this procedure Section V: Award of contract/concession Contract No: 1 V.2)Award of contract/concession V.2.1)Date of contract award decision: 27/04/2020 V.2.2)Information about tenders The contract has been awarded to a group of economic operators: no V.2.3)Name and address of the contractor/concessionaire Official name: Macure Pharma ApS National registration number: 35234748 Postal address: Hejrevej 39 Town: København NUTS code: DK Postal code: 2400 Country: Denmark The contractor/concessionaire will be an SME: no V.2.4)Information on value of the contract/lot/concession (excluding VAT) Initial estimated total value of the contract/lot/concession: 2 100 000.00 NOK Total value of the contract/lot/concession: 2 100 000.00 NOK V.2.5)Information about subcontracting Section VI: Complementary information VI.3)Additional information: VI.4)Procedures for review VI.4.1)Review body Official name: Øst-Finnmark tingrett Postal address: Postboks 54 Town: Vadsø Postal code: 9811 Country: Norway Internet address: [9]https://www.domstol.no/Enkelt-domstol/ost-finnmark-tingrett/ VI.4.2)Body responsible for mediation procedures Official name: Klagenemda for offentlige anskaffelser Postal address: Postboks 439 Sentrum Town: Bergen Postal code: 5805 Country: Norway E-mail: [10]postmottak@kofa.no Telephone: +47 55597500 Internet address: [11]http://www.kofa.no VI.4.3)Review procedure VI.4.4)Service from which information about the review procedure may be obtained VI.5)Date of dispatch of this notice: 29/04/2020 -------------------------------------------------------------------------------- Database Operation & Alert Service (icc-hofmann) for: The Office for Official Publications of the European Communities The Federal Office of Foreign Trade Information Phone: +49 6082-910101, Fax: +49 6082-910200, URL: http://www.icc-hofmann.de